Leadership

Our leaders have extensive experience and knowledge in the pharmaceutical industry. Their managerial and entrepreneurial skills had brought success to the business. Their learnings from the journeys they had taken made them more adept at developing the enterprise. Furthermore, their engagements in multinational pharmaceutical companies in the country had enriched their core competencies in performing their respective functions in the organization, thus, bringing success to Delex Pharma International, Inc (DPI). Meet the core leaders behind the impressive breakthrough of our company.

J.de Ruyter C. Oroceo

CEO & Chairman of the Board

He was able to institute a deserving pharmaceutical company in more than three decades of developing his craft in the healthcare industry. Let us recommence the paths that brought him to be the CEO and Chairman of the Board of Delex Pharma International Incorporated.

Read More >>

J.de Ruyter C. Oroceo - CEO & Chairman of the Board

He was able to institute a deserving pharmaceutical company in more than three decades of developing his craft in the healthcare industry. Let us recommence the paths that brought him to be the CEO and Chairman of the Board of Delex Pharma International Incorporated.

In 1989, Mr. Oroceo took pride in embracing the roles and responsibilities of a Hospital Sales Representative at Abbott Laboratories. It is one of the longest-standing global healthcare companies in innovative research and product manufacturing. After fifteen years of proving as a dedicated Sales Representative and District Sales Manager, he was promoted to a Product Manager from 2004 to 2008. The chance of exploring another pharmaceutical company had come his way after his 19 years of stint with Abbott. Therefore, the now-CEO leaped to become the Marketing Manager of Hospira Philippines. Following his managerial term was another opportunity for growth and development for Mr. Oroceo. He continued to broaden his horizon in the administrative realm as the General Manager of Globo Asiatico Enterprises from 2009 to 2010. Globo Asiatico is one of the leading health care distribution providers nationwide, which was the mother company of Delex for three years

With his proven leadership and expertise in business development, he reached the peak of the Executive ladder in the pharmaceutical industry. It has led to the founding of DPII in 2009, which he is now bravely and confidently heading. Simultaneously, he is the Chairman of the Board of DLX Holdings, Inc. and JMN Brothers Pharma Limited, Inc.

This year, he has proudly obtained a spot in the category of Global Filipino Executive of the Year, granted by SMART Communications. The criteria for excellence, that Mr. Ruyter exhibited include management achievement, financial contribution, recognition, pioneering social achievements, and social commitment.

Preliminary to his successful path was his college diploma in Bachelor of Science Degree in Medical Technology. He graduated in 1985 from Central Philippine University and later on became a Registered Medical Technologist. To support the booming business of Delex Pharma, he completed his Master’s Degree in Business Administration at Ateneo De Manila Graduate School of Business in 2017. Moreover, he is currently a Fellow (FICD) of the Institute of Corporate Directors. 

Now, he is proudly administering the board of leadership of the company while strategically working on the continuous success of the organization.

Ma. Lourdes Elvira P. Monesterio

Vice President for Marketing

Behind the flourishing marketing department of the company is a woman who has been recognized by CMO Asia with the PHILIPPINES WOMEN LEADERS Award 2019 and PIONEERING WOMAN LEADER 2020! Backing these awards are her attainments before becoming the VP for Marketing of Delex Pharma.

Read More >>

Ma. Lourdes Elvira P. Monesterio - VP for Marketing

Behind the flourishing marketing department of the company is a woman who has been recognized by CMO Asia with the PHILIPPINES WOMEN LEADERS Award 2019 and PIONEERING WOMAN LEADER 2020! Backing these awards are her attainments before becoming the VP for Marketing of Delex Pharma.

Her engagement in the field of pharmaceuticals commenced in 2004. She worked as a Professional Health Representative in Abbott Laboratories Philippines from 2004 to 2006. After contributing success to Abbott for two years, she found a new home of career growth at Hospira Philippines. She was then among the pioneers of the later company in 2006. With her dedication and competence, she advanced to become a District Sales Manager in 2008. In 2009, she became the number one District Sales Manager of Hospira Philippines. Ms. Monasterio did not fail in outwitting the challenges of her job. Instead, she has done an exemplary performance in leading the company’s sales record.

Subsequently, she was entrusted by Delex Pharma management as National Sales Manager. In 2013, she was promoted to Sales and Marketing Manager. Surprisingly, it was during her time that the company attained the highest growth in sales and market share. Indeed, this was a big leap for the organization. Ms. Monasterio continually strengthened and maximized the opportunities for the corporate brand through several digital platforms. It includes the launching of the ICU Forum community, which reinforces knowledge among intensivists and physicians. As technology advancement is a necessity, she has initiated a series of webinars for the ICU Forum. Along with this, she has implemented remote or online detailing initiatives between the company’s Medical Representatives and healthcare providers. Ms. Monasterio has also headed the launching of the Mobile Dosage Calculator App. She is currently strengthening the digital platforms of the company by leveraging its social marketing strategy. Moreover, she never ceased boosting the CSR programs of Delex Pharma.

With the achievements she fulfilled from her previous experiences, she became the VP for Marketing of Delex Pharma International Inc. At once, she is the President of DLX Holdings, Inc., and the Vice-President of JMN Brothers Pharma Limited Inc.

Before reaching her career paths, she graduated as a Cum Laude at the Universidad de Sta. Isabel in 2002. She earned a degree in Bachelor of Science majoring in Marketing and Management. Furthermore, she is completing her thesis for a Master’s Degree in Business Administration at San Beda University Graduate School, Philippines.

Noel L. Omandam

Vice President for Operations

Strengthening the pillars of the day-to-day supply and distribution operations of the company is Mr. Noel Omandam. He is an experienced and accomplished leader tantamount to the VPs for the Distribution of similar industries. He has previously surpassed different career challenges before gaining his current position.

Read More >>

Noel L. Omandam - VP for Operations

Strengthening the pillars of the day-to-day supply and distribution operations of the company is Mr. Noel Omandam. He is an experienced and accomplished leader tantamount to the VPs for the Distribution of similar industries. He has previously surpassed different career challenges before gaining his current position.

It was in the year 1980 when his employment started. He was assigned to the Manufacturing, Quality Assurance, and Production Planning & Inventory Control of Abbott Laboratories Philippines. After seventeen years, he obtained his notable breakthrough in sales as a Hospital Sales Representative under the Hospital Care Division in 1997. Because of his proven contributions to the company, he was promoted to District Sales Manager handling Mindanao from 2001 to 2004. As he merits excellence and passion at work, he received a Presidential Club award in 2002. In the succeeding years, Mr. Omandam became the District Sales Manager of Hospira Philippines after staying with Abbott for more than two decades. He was then one of the pioneers in the company as he handled the sales force of the Visayas and Mindanao area. He had never stopped proving his competencies. Thus, he earned the High Flyer’s Club Award in 2007. In the following year, he took charge of the Medical Devices business of Hospira in Manila.

After several years of gaining experience in the healthcare industry, he decided to join Delex Pharma International Inc. in 2010. He worked as the District Sales Manager. Subsequently, he secured the spot of becoming the National Sales Manager as he continually contributed success to the company. Eventually, he became the VP for Distribution at the same the Corporate Secretary and a Board Member of DPII. He is also the President of JMN Brothers Pharma Limited, Inc. and the Treasurer of DLX Holdings, Inc.

But before landing in the different professions, he graduated with a Bachelor of Science Degree in Chemical Engineering at the University of San Jose Recoletos in 1980. Currently, he is completing his thesis for a Master’s Degree in Business Administration at San Beda University Graduate School, Philippines. Moreover, he is currently a graduate (GICD) of the Institute of Corporate Directors.

Anthony T. Moraleda

Assistant Vice President for Sales

Mr. Moraleda is the current Assistant Vice President for Sales of Delex Pharma. He is capable of leading the company’s Sales department to go beyond the profit or market share goals. Part of his responsibility is the execution of plausible strategies and effective budget management in achieving the growth target. He also effectively manages the business financial collections of the organization.

Read More >>

Anthony T. Moraleda - Assistant VP for Sales

Mr. Moraleda is the current Assistant Vice President for Sales of Delex Pharma. He is capable of leading the company’s Sales department to go beyond the profit or market share goals. Part of his responsibility is the execution of plausible strategies and effective budget management in achieving the growth target. He also effectively manages the business financial collections of the organization.

Before reaching his current profession, he has started to amplify his career at Abbott Laboratories Philippines for twenty-one (21) years. He took full responsibility for performing his obligations as a Production Engineer. After two (2) years of exhibiting his expertise, Mr. Moraleda has made a bold move in his career, as he has delved into becoming a Medical Sales Representative. He has bagged the Top Presidential Award during his stint in the Sales department. Mr. Tony was then promoted as a Sales Specialist following his impressive breakthrough as a Sales Representative. He realized that his career shift was the right decision toward a greater opportunity.

Succeeding his outstanding milestone at Abbot, Mr. Tony was able to climb the corporate ladder. He has managed the different departments in the company, ranging from Sales, Trade Sales, SalesForce Effectiveness (SFE), and Supply Chain to Distribution. With his proven competencies, he has been assigned as a District Sales Manager, and eventually became the Regional Sales Manager. He has never ceased in contributing success to the organization. Thus, he has taken another remarkable stint in becoming a National Sales Manager and Sales and Supply Chain Director. He also extended his experience handling international distributions in Guam, Saipan, and American Samoa.

In 2013, Mr. Moraleda left Abbott and found a new opportunity at Advanced Nutritional Technologies (ANTECH) Inc. It is among the pharmaceutical companies in the country specializing in developing and distributing specialty pediatric healthcare products. He has assumed positions as a National Sales Manager and Supply Chain & Trade Director.

Six years later, he joined Delex Pharma as a National Sales Manager. With his evident capabilities in administering the Sales Department, he has been promoted to one of the highest ranks in the company — Assistant Vice President for Sales!

Furthermore, Mr. Moraleda graduated from Adamson University with a degree of Bachelor of Science in Chemical Engineering.

Melandrino M. Diego

I.T Manager

Mr. Diego is an experienced Information Technology manager. He delivers effectively and efficiently the computer system operations within the limits of requirements, specifications, costs, and timelines. Furthermore, he has extensive knowledge in the realm of Information Technology applications ranging from database analysis to the data integration process.

Read More >>

Melandrino M. Diego - I.T Manager

Mr. Diego is an experienced Information Technology manager. He delivers effectively and efficiently the computer system operations within the limits of requirements, specifications, costs, and timelines. Furthermore, he has extensive knowledge in the realm of Information Technology applications ranging from database analysis to the data integration process. Along with this, he heads the supervision, implementation, and maintenance of the company’s computing needs.

Before he became the organization’s I.T manager, he worked as an I.T officer at Terramedic Inc. in 2004, which is also a Pharmaceutical company. After gaining a year of work experience as an I.T officer, he worked as a Management Information System officer in IPCA, an Indian manufacturing company.

In 2002, Mr. Diego graduated from Far Eastern University-East Asia College of Information Technology, Manila. He gained a diploma with Bachelor of Science in Computer Information Systems, majoring in Network Engineering. He is currently taking up his Master’s Degree in Business Administration at San Beda University Graduate School, Philippines.

Ana Lyn P. Matienzo

Finance Manager

With her notable experience in the field of accounting, she can develop cohesive plans and strategies for the long-term financial goals of the company. Also, the investment activities of the organization rely on her expertise and direction. She ensures the proper management of the company’s funds, which includes cash flow forecasting and investment activities. 

Read More >>

Ana Lyn P. Matienzo - Finance Manager

With her notable experience in the field of accounting, she can develop cohesive plans and strategies for the long-term financial goals of the company. Also, the investment activities of the organization rely on her expertise and direction. She ensures the proper management of the company’s funds, which includes cash flow forecasting and investment activities. Let us have a run-own on her career highlights.

She has developed a remarkable portfolio of more than 20 years in the field of accounting that includes fifteen (15) years in the food industry with Golden Donuts, Inc. Back then, she was a Credit and Collection Supervisor from 1998 to 2000. After two successful years, she gained promotion as an Assistant General Accounting Manager from 2000 until 2011.  She provides financial statements and analyses to the Board of Directors.

Following her successful work experiences, she joined Delex Pharma in 2011 and became the Finance Manager of the company. She is currently the Corporate Secretary and; Board Member of DLX Holdings, Inc. and JMN Brothers Pharma Limited, Inc. Part of her remarkable contribution to the company’s business processes is the initiation of Systems Applications and Products (SAP). The system is currently being used as the Enterprise Resource Planning (ERP) of Delex Pharma. Ms. Matienzo has also maximized the use of internet banking to its stakeholders, as it is critical in the payment process. She is currently working with one of its partner banks on the implementation of a contactless collection system.

Moreover, Ms. Matienzo was able to implement various policies to strengthen the internal control system of the company. She has administered it in collaboration with Isla Lipana & Co. (a member of PWC Network), as the external auditor of the organization. Likewise, she ensures that the financial statements of the company adhere to the strictest protocols imposed by the various government authorities. Through this deed, she embodies one of the values of the company — INTEGRITY!

Ms. Matienzo graduated with a Bachelor of Science Degree in Accountancy at the University of the East, Manila, in 1994. She was a University Scholar back then. Further, Ms. Matienzo finished her Master’s Degree in Business Administration with distinction at San Beda University Graduate School in 2019.

Nilda Z. Cruz

HR & Manager

Ms. Nilda Zarate Cruz recently joined Delex Pharma on June 1, 2022. Nini as she is commonly called by her colleagues is a graduate of BS-Psychology at Saint Paul University Manila in 1999. In the same institution, she finished her Master in Business Administration major in Organizational Development in 2021.

Read More >>

Nilda Z. Cruz - HR & Manager

Ms. Nilda Zarate Cruz recently joined Delex Pharma on June 1, 2022. Nini as she is commonly called by her colleagues is a graduate of BS-Psychology at Saint Paul University Manila in 1999. In the same institution, she finished her Master in Business Administration major in Organizational Development in 2021.

She started her career in the pharmaceutical industry in 2005, as a Recruitment Specialist in Pascual Laboratories Inc. After two years in the company, she was promoted to Human Resource Supervisor in 2007. She handled the Recruitment, Compensation & Benefits, and Employee Relations overseeing the group of companies under PascualLab namely, ADP Pharma, Altermed, Pharex Health Corp, Pascual Consumer Healthcare Corp, Pharma Group including the Support Group.  Ms. Nini was a homegrown talent of PascualLab. She was able to rise from the ranks and was finally appointed as the Corporate HR Manager from 2014 to 2015.

In 2016, when PascualLab authorized the group of companies to operate in a silo, Pascual Consumer Healthcare Corporation (PCHC) absorbed Nini to become their dedicated HRAD Manager focusing on their business operations.  PCHC was then the sales and marketing organization of PascualLab. Succeeding her corporate stint, she decided to pursue her graduate studies program and looked for a new opportunity in the hospital industry. 

Prior to joining DELEX Pharma, she worked with De Los Santos Medical Center, a Metro Pacific Hospital as the Senior Manager for Human Resources Operations handling all the functions such as Recruitment, Training & Dev’t, OD, Compensation & Benefits, Employee Engagement and Labor Relations.  She stayed with DLSMC for more than one (1) year and has decided to go back to the pharma industry.

Maria Lirio Herrera-Guzman

Associate Regulatory Affairs & Quality Assurance Manager

She started her career in regulatory affairs sometime in August 2008. Her key roles are handling different products regulated by the Philippine Food and Drug Administration, such as Dental Anesthesia, dental medical devices and equipment, food supplements, and generic oral products from various local companies.

Read More >>

Maria Lirio Herrera-Guzman - Associate Regulatory Affairs & Quality Assurance Manager

She started her career in regulatory affairs sometime in August 2008. Her key roles are handling different products regulated by the Philippine Food and Drug Administration, such as Dental Anesthesia, dental medical devices and equipment, food supplements, and generic oral products from various local companies.

After several years, she found a career at Delex Pharma in May 2017 as the company’s Regulatory Affairs Pharmacist for drugs. She has expanded her knowledge as she grew and developed more skills with the company. With her proven expertise, she now heads the regulatory affairs and quality assurance department of Delex. 

Ms. Guzman was a graduate of Bachelor of Science in Pharmacy at the Royal & Pontifical University of the Philippines – University of Santo Tomas in 2007. She passed the Pharmacy Licensure Examination in the same year.

Evafrancis Monserrat M. Villamayor

Business Development Manager

Eva has had a multi-faceted career in the pharmaceutical industry for over thirty (30) years, ranging from business development, regulatory affairs, quality control or quality assurance, manufacturing, and hospital to sales. Her entire career revolved around both local and multinational companies. 

Read More >>

Evafrancis Monserrat M. Villamayor - Business Development Manager

Eva has had a multi-faceted career in the pharmaceutical industry for over thirty (30) years, ranging from business development, regulatory affairs, quality control or quality assurance, manufacturing, and hospital to sales. Her entire career revolved around both local and multinational companies. Here’s a glimpse of Ms. Eva’s corporate ladder.

Before her regional posting, she headed the Philippines office of Faulding Pharmaceutical Philippines (David Bull Lab, Australia).

Following her success in the Philippines, she held regional posts for over twenty (20) years handling Business Development, Regulatory Affairs, and Sales & marketing. Her last post was as Regional Manager (SEA) of Medochemie Singapore Pte. Ltd., where parts of her achievements were the following:

  • Established a steady stream of pipeline products to each distributor per country of responsibility (Hong Kong, Macau, Taiwan, Malaysia, Thailand, Philippines, Myanmar, the latest assignment includes China)
  • Contributed significant sales growth for each distributor/ country
  • Identified, evaluated & negotiated contracts with potential partners in each country, including China. 

Eight months later, after going back to the Philippines, she joined Delex Pharma International, Inc. as Business Development Manager. 

She is a BS Pharmacy graduate from the University of the Philippines, Diliman, and a licensed Pharmacist with earned units in Master of Business Administration in the same institution.

Gil Peter A. Coching

Shield Director

Mr. Coching serves as the SHIELD (Spiritual Holistic Integrated Empowered Leaders of Delex) Director of DPI. He is responsible for the planning, development, and delivery of comprehensive, multi-faith spiritual care services of the company. He does the development of effective working relationships within the organization while supporting and understanding the spiritual needs of the employees.

Read More >>

Gil Peter A. Coching - Shield Director

Mr. Coching serves as the SHIELD (Spiritual Holistic Integrated Empowered Leaders of Delex) Director of DPI. He is responsible for the planning, development, and delivery of comprehensive, multi-faith spiritual care services of the company. He does the development of effective working relationships within the organization while supporting and understanding the spiritual needs of the employees.

Mr. Coching was a corporate coach to several leading hospitals and private businesses in the country. These are Resorts World Manila, Mercury Drug (Head Office Branches), and Asian Development Bank, to name a few. Meanwhile, he is the current Treasurer of JMN Brothers Pharma Limited Inc.

He was a graduate of Bachelor of Science in Architecture at the University of Mindanao in 1988. He completed his Masters of Theology at the School of Theology, SVD Tagaytay in 1997, and Masters of Development Communication at the University of the Philippines in 2004.

TERMS

Copyrights

COPYRIGHTS

Copyrights © DELEX 2023. All rights reserved.

This website and its content are copyright of Delex Healthcare Group Inc. (D
Any redistribution or reproduction of any contents or images in any form is prohibited other than the following:

You may print or download to local hard disk extracts for your personal and non-commercial use only. You may not, except with our express written permission, distribute or commercially exploit any contents or images. You may not copy or transmit it or store it in any other website, blogs or social media pages, or other forms of the electronic retrieval system.

 

Disclaimers

DISCLAIMERS

DISCLAIMERS

 

Investing in any business involves risks, illiquidity, lack of dividends, loss of investment, dilution of shares, and should be done only as a part of a diversified portfolio. This presentation is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. This information has not been approved as a financial promotion, and you must carry out your own due diligence.

 

This presentation file is for informational purposes only and does not constitute an offer or solicitation to sell shares or securities in the Company or any related or associated company. Any such offer or solicitation will be made only by means of the Company’s confidential Offering Memorandum and in accordance with the terms of all applicable securities and other laws. None of the information or analyses presented are intended to form the basis for any investment decision, and no specific recommendations are intended.

 

Accordingly, this presentation file does not constitute investment advice or counsel or solicitation for investment in any security. This presentation file does not constitute or form part of, and should not be construed as, any offer for sale or subscription of, or any invitation to offer to buy or subscribe for, any securities, nor should it or any part of it form the basis of, or be relied on in any connection with, any contract or commitment whatsoever. Delex Healthcare Group Inc. (Delex), Delex Pharma International Inc. (Delex Pharma) and or DLX Holdings (DLX) expressly disclaims any and all responsibility for any direct or consequential loss or damage of any kind whatsoever arising directly or indirectly from: (i) reliance on any information contained on the website, (ii) any error, omission or inaccuracy in any such information or (iii) any action resulting therefrom.

 

RISK FACTORS

An investment in our Common Stock involves a high degree of risk. You should carefully consider the following risk factors, together with the other information contained in this Offering Circular, before purchasing our Common Stock. Any of the following factors could harm our business, financial condition, results of operations or prospects, and could result in a partial or complete loss of your investment. Some statements in this Offering Circular, including statements in the following risk factors, constitute forward-looking statements. Please refer to the section entitled “Cautionary Statement Regarding Forward-Looking Statements”.

 

Risks Relating to Our Financial Condition

We may require additional capital to support business growth, and this capital might not be available on acceptable terms, if at all.

 

We intend to continue to make investments to support our business growth and may require additional funds to respond to business challenges, including the need to develop new features and products or enhance our existing products, improve our operating infrastructure or acquire complementary businesses and technologies. Accordingly, we may need to engage in continued equity or debt financings to secure additional funds. If we raise additional funds through future issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of our common stock. Any debt financing, we secure in the future, could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. We may not be able to obtain additional financing on terms favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to continue to support our business growth and to respond to business challenges could be impaired, and our business may be harmed.

 

Risks Relating to Our Business and Industry

We may fail to obtain sufficient capital resources for future growth and other operational needs.

 

We require additional capital resources to pursue our growth strategy through organic expansion as well as strategic investments and acquisitions and to remain competitive by responding in a timely manner to technological changes or market demand. We require significant capital to build, maintain, operate and expand our research and development activities, develop more product range, secure more distribution rights, expand its global distribution channels, invest in manufacturer of healthcare products and provider of healthcare services.

 

We expect to meet our funding needs through cash flows from operations, securities offerings, bank borrowings and other external financing sources. Our ability to obtain additional financing will depend on several factors, including our financial condition, results of operations and cash flows. The increase in the interest rates and statutory deposit reserve ratios tightened credit and negatively affected the abilities of many companies to borrow from financial institutions. If we cannot obtain sufficient funding on acceptable terms or, to the extent required, receive necessary approvals for our financing plans from the regulatory authorities, we may not be able to successfully implement our business strategy, and our prospects could be materially and adversely affected.

 

We may experience significant losses from operations.

 

Even if we do generate operating income in one or more quarters in the future, subsequent developments in our industry, customer base, business or cost structure or an event such as significant litigation or a significant transaction may cause us to again experience operating losses. We may not become profitable for the long-term, or even for any

We may not be able to successfully identify acquisition targets or complete acquisitions or integrate the acquired businesses.

 

We may not be able to successfully identify acquisition targets or complete acquisitions or integrate the acquired businesses. One of our business strategies is to take advantage of the trend of consolidation in the highly fragmented healthcare industry by undertaking acquisition activities. Further, we intend to use part of the net proceeds that we receive from the listing to acquire domestic and overseas healthcare businesses. Through acquisitions, we aim to obtain advanced technologies, new products and other resources for our pharmaceutical manufacturing business, diagnostic products, and medical devices businesses, enter and expand our operations in the premium, specialty, and general healthcare service markets in the Philippines, and expand the coverage and network of our retail pharmacies in our existing and future target markets in the whole of Asia. Internationally, we plan to primarily acquire overseas generic drug manufacturing companies or specialty pharmaceutical companies with strong product portfolios, research, and development. These overseas pharmaceutical companies are expected to help us further expand our product lines and increase the sales of our products in the international markets. In addition, we may continue to identify, pursue, and consummate joint venture projects in the future.

 

Risks Relating To The Company’s Securities

 

We may never have a public market for our common stock or may never trade on a recognized exchange. Therefore, you may be unable to liquidate your investment in our stock.

 

There is no established public trading market for our securities. Our shares are not and have not been listed or quoted on any exchange or quotation system.

 

For our shares to be quoted, a market maker must agree to file the necessary documents with the National Association of Securities Dealers, which operates the OTCQB. In addition, it is possible that such application for quotation may not be approved and even if approved it is possible that a regular trading market will not develop or that if it did develop, will be sustained. In the absence of a trading market, an investor may be unable to liquidate their investment.

We do not expect to declare or pay dividends in the foreseeable future.

We do not expect to declare or pay dividends in the foreseeable future, as we anticipate that we will invest future earnings in the development and growth of our business. Therefore, holders of our Common Stock will not receive any return on their investment unless they sell their securities, and holders may be unable to sell their securities on favorable terms or at all.

 

 Our shares are subject to the penny stock rules, making it more difficult to trade our shares.

 

The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. If the price of our Common Stock is less than $5.00, our Common Stock will be deemed a penny stock. The penny stock rules require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive (i) the purchaser’s written acknowledgment of the receipt of a risk disclosure statement; (ii) a written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our Common Stock, and therefore stockholders may have difficulty selling their shares. 

 

Cautionary Statement Regarding Forward-Looking Statements

 

This Offering Circular contains various “forward-looking statements.” You can identify forward-looking statements by the use of forward-looking terminology such as “believes,” “expects,” “may,” “will,” “would,” “could,” “should,” “seeks,” “approximately,” “intends,” “plans,” “projects,” “estimates” or “anticipates” or the negative of these words and phrases or similar words or phrases. You can also identify forward-looking statements by discussions of strategy, plans or intentions. These statements may be impacted by several risks and uncertainties. The forward-looking statements are based on our beliefs, assumptions and expectations of our future performance considering all information currently available to us. These beliefs, assumptions and expectations are subject to risks and uncertainties and can change as a result of many possible events or factors, not all of which are known to us. If a change occurs, our business, financial condition, liquidity, and results of operations may vary materially from those expressed in our forward-looking statements. You should carefully consider these risks before you make an investment decision with respect to our Securities. For a further discussion of these and other factors that could impact our future results, performance, or transactions, see the section entitled “Risk Factors.”

 

We are selling the shares of this offering without an underwriter and may be unable to sell any shares.

 

This offering is self-underwritten, that is, we are not going to engage the services of an underwriter to sell the shares; we intend to sell our shares through our Chairman of our Board of Directors and CEO, Mr. Oroceo and Servebank Financial Inc., (Servebank), both of whom will receive no commissions. There is no guarantee that Mr. Oroceo or Servebank will be able to sell any of the shares. Unless they are successful in selling all of the shares of our Company’s offering, we may have to seek alternative financing to implement our business plan.

 

FORWARD LOOKING STATEMENTS

The statements contained herein may contain certain forward-looking statements relating to Delex Healthcare Group, Inc. or “Delex” that are based on the beliefs of Delex as well as assumptions made by and information currently available to Delex’s management. These forward-looking statements are, by their nature, subject to significant risks and uncertainties. These forward-looking statements include, without limitation, statements relating to Delex’s business prospects, future developments, trends and conditions in the industry and geographical markets in which Delex operates, its strategies, plans, objectives and goals, its ability to control costs, statements relating to prices, volumes, operations, margins, capital expenditures, overall market trends, risk management and exchange rates. When used herein, the words “anticipate”, “believe”, “could”, “estimate”, “expect”, “going forward”, “intend”, “may”, “ought to”, “plan”, “project”, “seek”, “should”, “will”, “would” and similar expressions, as they relate to Delex or Delex’s management, are intended to identify forward-looking statements. These forward-looking statements reflect Delex’s views at the time such statements were made with respect to future events and are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including any changes in the laws, rules and regulations relating to any aspects of Delex’s business operations, general economic, market and business conditions, including capital market developments, changes or volatility in interest rates, foreign exchange rates, equity prices or other rates or prices, the actions and developments of the Delex’s competitors and the effects of competition in the healthcare or related sectors, demand for, and price of, Delex’s products and services, various business opportunities that Delex may or may not pursue, changes in population growth and other demographic trends, including mortality, pandemics, morbidity and longevity rates, persistency levels, Delex’s ability to identify, measure, monitor and control risks in Delex’s business, including its ability to manage and adapt its overall risk profile and risk management practices, its ability to properly price its products and services, including capital expenditures and establish reserves for future policy benefits and claims, seasonal fluctuations and factors beyond Delex’s control. Subject to the requirements of the Listing Rules, Delex does not intend to update or otherwise revise such forward-looking statements, whether as a result of new information, future events or otherwise. As a result of these and other risks, uncertainties and assumptions, forward-looking events and circumstances discussed herein might not occur in the way Delex expects, or at all. Accordingly, you should not place reliance on any forward-looking information or statements. All forward-looking statements herein are qualified by reference to the cautionary statements set forth in this section.

 

Privacy Policy

PRIVACY POLICY

Your privacy is important to DELEX

This privacy statement provides information about the personal information that DELEX collects and how DELEX uses that personal information.

Personal Information Collection

DELEX may collect and use the following kinds of personal information:

Information about your use of this website Information about transactions carried out over this website.
Information that you provide to secure our services.

 

Using Personal Information

DELEX may use your personal information to:
Administer this website
Communicate with you.

Collect payments from you
Send account statements to you.

Publish information about you on the website.

Send invoices and demand payments from you.
Send information of products and or services to you.

Where DELEX discloses your personal information to its associates, partners, agents or sub-contractors for these purposes, the associates, partners, agent or sub-contractor in question will be obligated to use that personal information in accordance with the terms of this privacy statement.


In addition to the disclosures reasonably necessary for the purposes identified elsewhere above, DELEX may disclose your personal information to the extent that it is required to do so by law, in connection with any legal proceedings or prospective legal proceedings, and to establish, exercise or defend its legal rights.

Securing Your Data

DELEX will take reasonable technical and organizational precautions to prevent the loss, misuse, or alteration of your personal information.
DELEX will store all the personal information you provide on its secure servers. Information relating to electronic transactions entered via this website will be protected by encryption technology.

Cross-Border Data Transfers

Information which DELEX collects may be stored and processed in and transferred between any of the countries in which DELEX operates to enable the use of the information in accordance with this privacy policy.

In addition, personal information that you submit for publication on the website will be published on the internet and may be available around the world. You agree to such cross-border transfers of personal information.

Updating This Statement

DELEX may update this privacy policy by posting a new version on this website.
You should check this page occasionally to ensure you are familiar with any changes.

Other Websites

This website contains links to other websites
DELEX is not responsible for the privacy policies or practices of any third party.

 

Terms of Use

TERMS OF USE

Terms of Use

Welcome to our website. If you continue to browse and use this website, you are agreeing to comply with and be bound by the following terms and conditions of use, which together with our privacy policy govern DELEX’s relationship with you in relation to this website. If you disagree with any part of these terms and conditions, please do not use our website.


The terms, ‘DELEX or ‘us’ or ‘we’ or ‘Company’, refer to the owner of the website.

The term ‘you’ refers to the user or viewer of our website.


The use of this website is subject to the following terms of use:

The content of the pages of this website is for your general information and use only. It is subject to change without notice This website uses cookies to monitor browsing preferences.


Neither we nor any third parties provide any warranty or guarantee as to the accuracy, timeliness, performance, completeness or suitability of the information and materials found or offered on this website for any particular purpose. You acknowledge that such information and materials may contain inaccuracies or errors and we expressly exclude liability for any such inaccuracies or errors to the fullest extent permitted by law

Your use of any information or materials on this website is entirely at your own risk, for which we shall not be liable It shall be your own responsibility to ensure that any products, services or information available through this website meet your specific requirements.

 
This website contains material which is owned by or licensed to us. This material includes, but is not limited to, the logo, design, layout, look, appearance, and graphics. Reproduction is prohibited other than in accordance with the copyright notice, which forms part of these terms and conditions. All trademarks reproduced in this website, which is not the property of, or licensed to, the operator are acknowledged on the website Unauthorized use of this website may give rise to a claim for damages and/or be a criminal offense.


From time to time this website may also include links to other websites. These links are provided for your convenience to provide further information. Links to other websites do not signify that we endorse the website(s). We have no responsibility for the content of the linked website(s). Your use of this website and any dispute arising out of such use of the website is subject to the laws of the Philippines and the United States of America (USA).

© 2024 DELEX Healthcare Group. All Rights Reserved.